Menu
Log in
Forgot password
Log in
Forgot password

News

  • Home
  • Resources
  • Literature Updates
  • Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.

30 Aug 2015 12:19 AM | Anonymous

Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, van Laarhoven HW, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, Ten Kate FJ, Creemers GM, Punt CJ, Plukker JT, Verheul HM, Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS study group.

Lancet Oncol. 2015 Aug 5. pii: S1470-2045(15)00040-6. doi: 10.1016/S1470-2045(15)00040-6. [Epub ahead of print]

PMID: 26254683

http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00040-6/abstract

Affiliated Societies



International  Interdisciplinary  Everything Esophageal


The International Society for Diseases of the Esophagus is a 501(c)3 non-profit organization. © International Society for Disease of the Esophagus – ISDE 2024 | Any unauthorized use or reproduction of the content is prohibited without explicit permission.

General Inquiries: info@isde.net
Membership Questions: membership@isde.net

Powered by Wild Apricot Membership Software